Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics. 

Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.

Japanese firm's decision to end development of entinostat in its licensed territories marks possibly final blow to development of the HDAC inhibitor in breast cancer. 

The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.